Journals / Bezmiâlem Science / 2015 / Cilt: 3 - Sayı: 2

Östrojen Reseptörü Pozitif/Progesteron Reseptörü Negatif Meme Karsinomları: Özel İlgiyi Hak Eden Bir Subgrup

Estrogen Receptor Positive/Progesterone Receptor Negative Breast Carcinomas: A Subgroup Deserves Particular Interest

Pages
29–32
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Revealing the mechanisms causing these differences will enhance the success of breast cancer therapy

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Breast carcinomas positive for the estrogen receptor (ER+) but negative for the progesterone receptor (PR−) have unfavorable prognostic features and are resistant to tamoxifen therapy.
📊
Key Findings & Data:The goal of this study was to highlight the significance of PR− breast carcinomas.
💡
Conclusion & Impact:Revealing the mechanisms causing these differences will enhance the success of breast cancer therapy
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Breast carcinomas positive for the estrogen receptor (ER+) but negative for the progesterone receptor (PR−) have unfavorable prognostic features and are resistant to tamoxifen therapy. The goal of this study was to highlight the significance of PR− breast carcinomas. Methods: Therefore, 146 breast carcinomas comprising 87 ER+/ PR+ and 59 ER+/PR− carcinomas were examined. These two groups were compared in terms of age; tumor type; tumor size; histologic grade; presence of an in situ component; lymphovascular and perineural invasion; and ER, PR, c-Erb B2, Ki-67, and epidermal growth factor receptor (EGFR) status. Results: While the number of metastatic lymph node and related pN2+pN3 tumors were found to be significantly higher in the ER+/PR− group, the differences with respect to the tumor size, metastatic lymph node size, and frequency of lymphovascular invasion were nearly significant. Conclusion: ER+/PR− tumors have an unfavorable prognosis and show a clinical behavior closer to triple negative ones, although classified as luminal tumors. Revealing the mechanisms causing these differences will enhance the success of breast cancer therapy

Özet

Amaç: Östrojen reseptörü pozitif, progesteron reseptörü negatif meme karsinomları daha kötü prognozlu ve tamoksifene direnç- li tümörlerdir. Bu çalışmada amaç bu grup tümörlerin önemine dikkat çekmektir. Yöntemler: Bu amaçla iki merkeze ait 87si ER+/PR+, 59u ER+/ PR- toplam 146 meme karsinomu incelenmiştir. Bu iki grup; hasta yaşı, tümör tipi ve çapı, histolojik grade, lenf nodülü (LN) durumu, multifokalite, in situ komponent varlığı, lenfovasküler (LVİ) ve perinöral invazyon (PNİ) varlığı gibi özellikler ve ER, PR, c-Erb B2, Ki-67, EGFR durumları açısından karşılaştırılmıştır. Bulgular: Metastazlı lenf nodülü sayısı ve bununla ilişkili olarak pN2+pN3 evre tümörler ER+/PR- grupta anlamlı olarak fazla bulunurken, tümör çapı, metastazlı lenf nodülü boyutu ve lenfovasküler invazyon sıklığı da anlamlıya yakın yüksek olarak saptanmıştır. Sonuç: ER+/PR- tümörler luminal tipte olsalar da daha kötü prognozlu ve klinik davranışları triple negatif gruba daha yakındır. Bu farklılığı oluşturan mekanizmaların ortaya çıkarılması meme kanseri tedavisinde başarıyı artıracaktır.

🔖

Cite This Article

GÜCİN, Z., GEÇER, M. Ö., BÜYÜKPINARBAŞILI, N., SÖNMEZ, C., ERSOY, Y. E., MÜSLÜMANOĞLU, M. (2015). Östrojen Reseptörü Pozitif/Progesteron Reseptörü Negatif Meme Karsinomları: Özel İlgiyi Hak Eden Bir Subgrup. Bezmiâlem Science, Cilt: 3 - Sayı: 2, 29–32. https://ajindex.com/articles/352590

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progeseron receptor loss in breast cancer and its implication for endocrine therapy. J Clin Oncol 2005
  2. [CrossRef] 2. Zhang C, Mori M, Gao S, Li A, Hoshino I, Aupperlee MD, et al. Tip30 deletion in MMTV-Neu mice leads to enhanced egfr signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors. Cancer Res 2010
  3. 10224-33. [CrossRef] 3. Fukua SA, Cui Y, Lee AV, Osborne CK, Hortwitz KB. Insights into the role of progesteron receptors in breast cancer. J Clin Oncol 2005
  4. [CrossRef] 4. Thakkar JP, Mehta DG. A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist 2011
  5. [CrossRef] 5. Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, et al. Progesterone receptor ısoform-specific promoter methylation: association of prapromoter methylation with worse outcome in breast cancer patients. Clin Cancer Res 2011
  6. [CrossRef] 6. Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, et al. Poor prognosis of single hormone receptor positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer 2015
  7. [CrossRef] 7. Bogina G, Bortesi L, Marconi M, Venturini M, Lunardi G, Coati F, et al. Comparision of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesteron receptor loss. Virchows Arch 2011
  8. [CrossRef] 8. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005
  9. [CrossRef] 9. Lydon JP, Edwards DP. Finally! A model for progesteron receptor action in normal human breast. Endocrinology 2009
  10. [CrossRef] 10. Jacobsen BM, Schittone SA, Richer JK, Hortwitz B. Progesteron-independent effects of human progesteron receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol 2004
  11. [CrossRef] 11. Badovinac-Crnjevic T, Jakic-Razumovic J, Podolski P, Plestina S, Sarcevic B, Munjas R, Vrbanec D. Significance of epidermal growth factor receptor expression in breast cancer. Med Oncol 2011
  12. 28(Suppl 1): S121-8. [CrossRef] 12. Abd El-Rehim DM, Pinder SE, Pai